Gambaran Umum
Oramed Pharmaceuticals Inc., based in the United States, operates within the biopharmaceutical industry, primarily focusing on the development of oral drug delivery systems. A standout project from Oramed is its proprietary Oral Insulin capsule, aimed at revolutionizing the treatment of diabetes by facilitating insulin absorption when taken orally, which traditionally has been administered only via injection. Additionally, the company is advancing an oral GLP-1 receptor agonist capsule, catering to type 2 diabetes. These innovations align with Oramed’s strategic focus on improving bioavailability and patient compliance, thus potentially shifting paradigms in diabetes management and other therapeutic areas requiring peptide-based treatments.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Oramed Pharmaceuticals Inc. per 2025 Jun 30 adalah 2.00 MM.
- Nilai operating income untuk Oramed Pharmaceuticals Inc. per 2025 Jun 30 adalah -13.67 MM.
- Nilai net income untuk Oramed Pharmaceuticals Inc. per 2025 Jun 30 adalah -24.16 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 2.00 | -13.67 | -24.16 |
2025-03-31 | 2.00 | -14.32 | -28.24 |
2024-12-31 | -12.78 | -19.06 | |
2024-09-30 | 0.00 | -13.06 | 4.46 |
2024-06-30 | 0.00 | -12.87 | 20.86 |
2024-03-31 | 0.67 | -13.52 | 10.46 |
2023-12-31 | 1.34 | -15.77 | 5.53 |
2023-09-30 | 2.02 | -21.63 | -16.35 |
2023-06-30 | 2.70 | -26.93 | -20.19 |
2023-03-31 | 2.70 | -34.55 | -29.53 |
2022-12-31 | 2.70 | -40.60 | -36.56 |
2022-09-30 | 2.71 | -49.30 | -46.28 |
2022-06-30 | 2.71 | -48.59 | -46.48 |
2022-03-31 | 2.71 | -41.63 | -39.76 |
2021-12-31 | 2.71 | -36.98 | -35.00 |
2021-11-30 | 2.70 | -26.46 | -24.56 |
2021-08-31 | 2.70 | -24.22 | -22.24 |
2021-05-31 | 2.70 | -19.83 | -18.38 |
2021-02-28 | 2.70 | -15.99 | -15.46 |
2020-12-31 | 2.71 | -22.68 | -21.97 |
2020-11-30 | 2.71 | -15.15 | -14.54 |
2020-08-31 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.59.
- laba per saham yang terdilusi untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.60.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -0.59 | -0.60 |
2025-03-31 | -0.69 | -0.71 |
2024-12-31 | -0.47 | -0.48 |
2024-09-30 | 0.11 | 0.11 |
2024-06-30 | 0.51 | 0.51 |
2024-03-31 | 0.26 | 0.26 |
2023-12-31 | 0.14 | 0.14 |
2023-09-30 | -0.41 | -0.41 |
2023-06-30 | -0.51 | -0.51 |
2023-03-31 | -0.75 | -0.75 |
2022-12-31 | -0.94 | -0.94 |
2022-09-30 | -1.08 | -1.08 |
2022-06-30 | -1.11 | -1.11 |
2022-03-31 | -1.00 | -1.00 |
2021-12-31 | -0.94 | -0.94 |
2021-11-30 | -0.77 | -0.77 |
2021-08-31 | -0.78 | |
2021-05-31 | -0.70 | -0.70 |
2021-02-28 | -0.63 | -0.63 |
2020-12-31 | -0.90 | -0.90 |
2020-11-30 | -0.66 | -0.66 |
2020-08-31 | -0.56 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Oramed Pharmaceuticals Inc. per 2025 Jun 30 adalah -16.07 MM.
- Nilai cash from investing activities untuk Oramed Pharmaceuticals Inc. per 2025 Jun 30 adalah -50.07 MM.
- Nilai kas dari aktivitas pendanaan untuk Oramed Pharmaceuticals Inc. per 2025 Jun 30 adalah -2.86 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -16.07 | -50.07 | -2.86 |
2025-03-31 | -10.46 | 99.44 | -33.04 |
2024-12-31 | -8.41 | 105.82 | -52.04 |
2024-09-30 | -7.92 | 120.39 | -75.84 |
2024-06-30 | -1.51 | 79.53 | -0.00 |
2024-03-31 | -6.22 | -29.84 | 30.55 |
2023-12-31 | -10.29 | -73.04 | 51.98 |
2023-09-30 | -16.94 | -91.78 | 81.15 |
2023-06-30 | -18.49 | -15.42 | 10.92 |
2023-03-31 | -24.34 | 9.65 | 10.92 |
2022-12-31 | -27.92 | 30.21 | 10.78 |
2022-09-30 | -39.32 | -257.74 | 90.58 |
2022-06-30 | -42.63 | -288.82 | 126.45 |
2022-03-31 | -38.81 | -301.14 | 154.98 |
2021-12-31 | -33.37 | -297.74 | 181.72 |
2021-11-30 | -21.93 | -124.01 | 162.87 |
2021-08-31 | -21.18 | -23.76 | 102.89 |
2021-05-31 | -17.50 | 16.25 | 49.35 |
2021-02-28 | -15.22 | -4.38 | 47.47 |
2020-12-31 | -24.79 | -7.21 | 39.00 |
2020-11-30 | -15.60 | 3.00 | 24.36 |
2020-08-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.65.
- p/tbv untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.65.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 0.65 | 0.65 | |
2025-03-31 | 0.61 | 0.61 | |
2024-12-31 | 0.60 | 0.60 | |
2024-09-30 | 4.85 | 0.57 | 0.57 |
2024-06-30 | 10.41 | 0.66 | 0.66 |
2024-03-31 | 20.68 | 0.70 | 0.70 |
2023-12-31 | -5.70 | 0.63 | 0.63 |
2023-09-30 | -5.21 | 0.70 | 0.70 |
2023-06-30 | -4.84 | 0.95 | 0.95 |
2023-03-31 | -2.38 | 0.58 | |
2022-12-31 | 3.07 | 3.07 | |
2022-09-30 | 1.64 | 1.64 | |
2022-06-30 | -4.46 | 1.09 | 1.09 |
2022-03-31 | -13.59 | 1.96 | 1.96 |
2021-12-31 | -24.42 | 4.66 | 4.66 |
2021-11-30 | -32.75 | 6.25 | 6.25 |
2021-08-31 | 0.00 | 9.02 | 9.02 |
2021-05-31 | -8.20 | 2.18 | 2.18 |
2021-02-28 | -2.46 | 1.92 | 1.92 |
2020-12-31 | -6.32 | 4.92 | 4.92 |
2020-11-30 | -8.68 | 4.47 | 4.47 |
2020-08-31 | -10.78 | 3.77 | 3.77 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -1.59.
- EBIT (3 tahun) / EV untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.49.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -1.59 | -0.49 |
2025-03-31 | -0.47 | -0.36 |
2024-12-31 | 0.14 | -0.17 |
2024-09-30 | 0.47 | -0.30 |
2024-06-30 | 0.08 | -0.17 |
2024-03-31 | 0.03 | -0.15 |
2023-12-31 | -0.10 | -0.19 |
2023-09-30 | -0.21 | -0.32 |
2023-06-30 | -0.26 | -0.28 |
2023-03-31 | -0.82 | -0.68 |
2022-12-31 | -0.11 | -0.07 |
2022-09-30 | -0.22 | -0.13 |
2022-06-30 | -0.28 | -0.16 |
2022-03-31 | -0.08 | -0.06 |
2021-12-31 | -0.05 | -0.04 |
2021-11-30 | -0.04 | -0.03 |
2021-08-31 | ||
2021-05-31 | -0.20 | -0.16 |
2021-02-28 | -0.56 | -0.41 |
2020-12-31 | -0.18 | -0.13 |
2020-11-30 | -0.13 | -0.12 |
2020-08-31 | -0.11 | -0.12 |
Efektivitas Manajemen
- roa untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.15.
- roe untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.16.
- roic untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.20.
- croic untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.40.
- ocroic untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -0.07.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.15 | -0.16 | -0.20 | 0.40 | -0.07 |
2025-03-31 | -0.09 | -0.12 | -0.13 | 0.31 | -0.06 |
2024-12-31 | 0.02 | 0.03 | 0.03 | 0.23 | -0.05 |
2024-09-30 | 0.09 | 0.14 | 0.10 | 0.37 | -0.01 |
2024-06-30 | 0.07 | 0.07 | 0.05 | -0.03 | -0.03 |
2024-03-31 | 0.03 | 0.04 | 0.03 | -0.15 | -0.05 |
2023-12-31 | -0.10 | -0.11 | -0.07 | -0.12 | -0.08 |
2023-09-30 | -0.12 | -0.13 | -0.13 | -0.15 | -0.12 |
2023-06-30 | -0.18 | -0.19 | -0.13 | -0.15 | -0.12 |
2023-03-31 | -0.21 | -0.23 | -0.20 | -0.03 | -0.16 |
2022-12-31 | -0.25 | -0.27 | -0.30 | -1.34 | -0.26 |
2022-09-30 | -0.36 | -0.40 | -0.30 | -1.34 | -0.26 |
2022-06-30 | -0.49 | -0.57 | -0.30 | -1.33 | -0.28 |
2022-03-31 | -0.40 | -0.50 | -0.24 | -1.13 | -0.24 |
2021-12-31 | -0.54 | -0.79 | -0.21 | -0.89 | -0.18 |
2021-11-30 | -0.54 | -0.79 | -0.14 | 0.10 | -0.18 |
2021-08-31 | -0.50 | -0.68 | -0.19 | 0.50 | -0.18 |
2021-05-31 | -0.40 | -0.54 | -0.26 | 0.69 | -0.25 |
2021-02-28 | -0.71 | -1.28 | -0.76 | 0.24 | -0.86 |
2020-12-31 | -0.71 | -1.28 | -0.76 | 0.24 | -0.54 |
2020-11-30 | -0.47 | -0.85 | -0.50 | 0.41 | -0.54 |
2020-08-31 | -0.33 | -0.59 | -0.35 | 0.48 | -0.38 |
Gross Margins
- marjin kotor untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.01.
- marjin bersih untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -14.12.
- marjin operasi untuk Oramed Pharmaceuticals Inc. pada 2025 Jun 30 adalah -7.16.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.01 | -14.12 | -7.16 |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | 1.00 | 15.51 | -20.06 |
2024-03-31 | 1.00 | 4.12 | -11.77 |
2023-12-31 | 1.00 | -8.09 | -10.70 |
2023-09-30 | 1.00 | -7.47 | -9.96 |
2023-06-30 | 1.00 | -7.47 | -9.96 |
2023-03-31 | 1.00 | -10.93 | -12.78 |
2022-12-31 | 1.00 | -17.06 | -18.18 |
2022-09-30 | 1.00 | -17.06 | -18.18 |
2022-06-30 | 1.00 | -17.14 | -17.92 |
2022-03-31 | 1.00 | -14.66 | -15.35 |
2021-12-31 | 1.00 | -12.91 | -13.63 |
2021-11-30 | 1.00 | -9.09 | -9.79 |
2021-08-31 | 1.00 | -8.23 | -8.96 |
2021-05-31 | 1.00 | -6.81 | -7.34 |
2021-02-28 | 1.00 | -8.10 | -8.36 |
2020-12-31 | 1.00 | -8.10 | -8.36 |
2020-11-30 | 1.00 | -5.36 | -5.59 |
2020-08-31 | 1.00 | -4.25 | -4.34 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1176309 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |